SCHEDULE: Millennium Entities Confirm Tenaya Therapeutics Stake

Several entities affiliated with Millennium Management have filed a Schedule 13G, confirming their beneficial ownership of Tenaya Therapeutics' common stock.

Summary

• This filing is a Schedule 13G, which is an informational filing used by beneficial owners of more than 5% of a class of a company's registered equity securities.
• The filing confirms that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander are reporting beneficial ownership of Tenaya Therapeutics, Inc. common stock.
• The reporting entities collectively hold a significant stake, with percentages ranging from 5.2% to 5.2% across the named entities.
• The filing is made in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, indicating a joint filing agreement among the parties.
• The date of the event requiring this filing is August 17, 2026, and the agreement is dated August 21, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, confirming existing beneficial ownership stakes rather than announcing new strategic developments or financial performance.

Positives

• Confirmation of a substantial institutional investor's stake in Tenaya Therapeutics, Inc., which can be seen as a vote of confidence.
• The filing clearly delineates the beneficial ownership structure among related entities.

Negatives

• The filing does not provide any new financial information, strategic updates, or performance metrics for Tenaya Therapeutics, Inc.
• It is an informational filing that does not offer insights into the company's operational health or future prospects.

Risks

• The filing itself does not introduce new risks, but the concentration of ownership by a single large entity could potentially influence market dynamics or corporate governance decisions.

Future Outlook

This filing is purely informational regarding ownership and does not contain any forward-looking statements or guidance for Tenaya Therapeutics, Inc.

Management Comments

• The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
• The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large investment firms accumulating significant stakes in publicly traded companies, particularly in the biotechnology sector where Tenaya Therapeutics operates. This filing confirms a substantial, established position rather than a new entry or exit.

Stakeholder Impact

• Shareholders: The confirmation of a significant stake by Millennium entities may provide some stability or signal continued institutional interest, but the filing itself does not alter existing ownership or control dynamics.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership of Tenaya Therapeutics, Inc. common stock.
• Future filings will be made as required by regulations if ownership levels change significantly.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Tenaya Therapeutics, Millennium Management, Institutional Investor, Common Stock, Securities Exchange Act